Hikma Pharmaceuticals Public annual total assets
2020
2021
2022
2023
2024
2025
Hikma Pharmaceuticals Public Total Assets Growth & History (HIK)
Hikma Pharmaceuticals Public's total assets was $5.67B for fiscal 2025.
View full Hikma Pharmaceuticals Public company overviewHikma Pharmaceuticals Public annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5.67B | $538.0M | +10.48% |
| 2024 | 2024-12-31 | $5.13B | $453.0M | +9.68% |
| 2023 | 2023-12-31 | $4.68B | $209.0M | +4.67% |
| 2022 | 2022-12-31 | $4.47B | $99.0M | +2.26% |
| 2021 | 2021-12-31 | $4.37B | $237.0M | +5.73% |
| 2020 | 2020-12-31 | $4.13B | — | — |
Hikma Pharmaceuticals Public quarterly total assets
Q4.24
Q2.25
Q4.25
Q2.26
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.83B | $276.0M | +4.97% |
| Q4 2025 | 2025-12-31 | $5.67B | $538.0M | +10.48% |
| Q2 2025 | 2025-06-30 | $5.55B | — | — |
| Q4 2024 | 2024-12-31 | $5.13B | — | — |
Hikma Pharmaceuticals Public total assets trends
Over the last five fiscal years, Hikma Pharmaceuticals Public's total assets increased from $4.13B to $5.67B, a change of $1.54B. The latest reported quarter, Q2 2026, shows $5.83B.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
reported total assets
TickerStat uses total assets reported in company official filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hikma Pharmaceuticals Public source filings ↗Community posts
Hikma’s epinephrine nasal spray advances into regulatory review
Hikma ($HIK) said regulators in the United States, Europe and the UK have accepted submissions for its investigational epinephrine nasal spray for review. The company has also filed in Canada and intends to expand submissions to additional ...